Hormonal and intrauterine contraception for women aged 40 years and older "The use of the levonorgestrel intrauterine device effectively treats heavy menstrual bleeding, even when associated with adenomyosis or leiomyomas, and is as effective as endometrial ablation in reducing heavy menstrual bleeding."
sterilization, 19 .6% on male sterilization, 11.1% on oral contraceptives (OCs), 8.8% on con doms, 4.2% on intrauterine devices (IUDs) and 1.1% on depot medroxyprogesterone acetate (DMPA). The USA has had higher sterilization rates compared with other developed countries [4] . Since longacting reversible contraceptives, collectively known as LARC (IUDs and con traceptive implants), provide effectiveness com parable to that of sterilization and are substan tially more cost effective than sterilization, use of these methods should be promoted among older women as they are among younger women.
Contraceptive use in women aged 40 years or older: is it riskier?
The added risks of pregnancy for women aged 40 years and older must be weighed against the risks of contraceptive use. Risks associated with the use of some methods may increase with age and additional comorbidities. For example, although the incidence of venous (deep venous thrombosis and pulmonary embolism) and arte rial (myocardial infarction and cerebrovascular accident) events are low, these risks increase with age. This should be considered before initiat ing a contraceptive in a woman aged 40 years or older. However, because lean, healthy, non smoking women are at low risk for these rare events, they can use any method, including com bined methods (estrogen-progestin pills, patch and vaginal ring), until menopause [101] . Since older reproductive age women are less fecund and more compliant in using contraception, the failure rate of combined methods is lower in this group of women.
The most effective reversible methods of con traception are LARC methods: the copper and progestin IUDs and the progestin implant. Since the copper IUD is nonhormonal, and the hor monal IUD and implant do not contain estro gen, their use is not associated with an increased risk of cardiovascular events. In large prospective
Is contraception needed for women aged 40 years & older who do not desire to be pregnant?
In 2008, there were 274 induced abortions per 1000 live births among women 40 years of age or older; this ratio was higher than all age groups except for young women and adolescents (≤24 years) [1] .
Overall, the pregnancy rate in women over 40 years of age is low. In 2011, the fertility rate in the USA among women aged 40-44 and 45-49 years was 10.3 births per 1000 women and 0.7 per 1000 women, respectively. This com pares with 107.2 births per 1000 women aged 25-29 years. Women over 40 years of age have lower fecundity (chance of birth per menstrual cycle) and, therefore, take longer to conceive. In one study, the fecundity of women younger than 35 years of age was 0.2 compared with 0.12 for women aged 35-40 years and 0.06 for women over the age of 40 years [2] . Nevertheless, the age related decline in fecundity does not provide the basis for reliable contraception. Women of older reproductive age who do not wish to conceive need to use effective contraception until menopause.
Women over the age of 40 years who conceive are more likely than younger women to suffer adverse consequences. Older gravidae experi ence an increased risk of spontaneous abortion and chromosomal abnormalities, as well as a higher incidence of gestational diabetes, hyper tension, placenta previa, cesarean delivery, peri natal mortality and maternal mortality [3] . In the USA, 48% of pregnancies among women aged 40 years and older are unintended. Each of these observations underscore the importance of effective contraception for women of older reproductive age who desire it. trials of users of progestinonly methods (pills, injections, implants or IUDs), no substantial increase in the overall incidence of venous throm boembolism (VTE), myocardial infarction or cerebrovascular accidents has been noted [5] [6] [7] . Therefore, safe, effective options are available for the highrisk woman over 40 years of age.
"Women of older reproductive age who do not wish to conceive need to use effective contraception until menopause."
The use of combined methods doubles the risk of VTE for women of reproductive age, from four to five per 10,000 to eight to ten per 10,000 womenyears [8] . Since pregnancy increases VTE risk by sixtimes, the benefits of any contracep tive use outweigh the risks of unintended preg nancy. However, conditions such as obesity, diabetes, hypertension and migraines, as well as cigarette smoking, raise an individual's base line risk for adverse cardiovascular outcomes. For women at elevated risk for cardiovascular events, the inherent risks of their condition com pounded with the risk of using combined meth ods is typically too high. For example, among OC users, obesity (BMI >30) further increases VTE risk by approximately three times [9] . In addition, the risk of VTE increases with age; the incidence of VTE in reproductive aged women (five per 10,000 womenyears) is less than half the rate of VTE in women of all ages (11 per 10,000 womenyears) [8] . The American Col lege of Obstetricians and Gynecologists advises caution when prescribing combined methods to obese women over 35 years of age. The US CDC recommends that for women over 40 years of age who have cardiovascular risk factors, combined methods should only be used when no other methods are available or acceptable [101] .
What are the noncontraceptive benefits of contraception for women aged 40 years & older?
Approximately 4-6 years prior to menopause, women will enter the perimenopause and will likely experience changes in menstrual bleed ing such as excessive or irregular menstruation, and vasomotor symptoms, such as hot flashes and night sweats. Hormonal contraceptives are treatment options for these conditions.
The use of the levonorgestrel IUD (LNG IUD) effectively treats heavy menstrual bleed ing, even when associated with adenomyosis or leiomyomas, and is as effective as endometrial ablation in reducing heavy menstrual bleeding [10] . The LNGIUD leads to a 97% reduction in menstrual blood loss by 12 months. Although irregular bleeding can occur initially, amenorrhea rates of 20-80% have been reported at 12 months [11] . In addition, the LNGIUD has been found comparable to hysterectomy in improving hema tologic parameters and quality of life [12] . The LNGIUD is licensed in the UK for protection from endometrial hyperplasia during use of estro gen therapy by perimenopausal and menopausal women [11] . This provides an excellent option for women who need contra ception or suppression of abnormal uterine bleeding. Use of injectable contraception (or DMPA) also leads to high rates of amenorrhea and is an option for the treatment of heavy menstrual bleeding, although it has been studied less for this indication [13] .
Use of combination contraceptives results in regular withdrawal bleeding, reduces menstrual blood loss, increases hemoglobin concentrations and is supported in clinical practice guidelines [11] . Combination contraceptives can also relieve severe vasomotor symptoms. Perimenopausal women taking OCs with 21 active pills may experience hot flashes during hormonefree days. These women may benefit from extended or con tinuous combination contraceptive regimens or monthly formulations that include fewer than 7 hormonefree days [10] .
"With the availability of long-acting reversible contraceptives, almost all women can use safe, effective contraception options until menopause."
A reduction in the risk of endometrial and ovarian cancer represents another benefit for women over 40 years of age using contracep tives. Compared with nonusers, use of estrogen containing OCs is associated with a 50% lower risk of endometrial cancer [10, 14] . The longer a woman uses estrogencontaining OCs, the lower her risk of endometrial cancer, although use for as little as 12 months confers moderate protec tion. The use of DMPA and the copper IUD are also associated with a reduction in risk of endo metrial cancer [15] . Although no epidemiologic data address the risk of endometrial cancer in women who have used the LNGIUD, a sub stantial literature has documented the efficacy of this device in treating endometrial hyperplasia and in preventing endometrial hyperplasia in women using menopausal estrogen therapy [11] .
There is also robust evidence that use of OCs reduces risk of ovarian cancer. A collaborative metaanalysis reviewed 45 studies that com pared users of OCs to neverusers, finding a 27% reduced risk of ovarian cancer for users compared with neverusers. The relative risk decreased by 20% for every 5 years of use, and the protective effect was still present 30 years after stopping [16] . DMPA use and tubal steriliza tion are also associated with a decreased ovarian cancer risk [17, 18] .
Can women safely use contraception until the age of menopause?
With the availability of LARC, almost all women can use safe, effective contraception options until menopause. The copper IUD can be used until menopause, defined as amenorrhea for at least 1 year in a woman 50 years of age or older. Use of lesseffective barrier methods may also be acceptable, if the risks of unintended pregnancy are determined to be low based on frequency of intercourse or number of co morbidities. Pro gestinonly methods may be continued up to 55 years of age since amenorrhea is a common side effect and, therefore, cannot be used as a marker for diagnosing menopause. If women develop contraindications, including breast cancer or worsening cardiovascular disease, the benefits of decreased bleeding and endometrial protection may outweigh risks of continued offlabel use [5] [6] [7] . Alternatively, switching to a nonhormonal method may be considered.
"There are no contraceptives that are contraindicated based on age alone." Lean, healthy, nonsmoking women of repro ductive age are at low risk for cardiovascular events, and may use combined methods until 55 years of age. As with progestinonly methods, using amenorrhea to diagnose menopause may not be reliable. Likewise, assessing folliclestimu lating hormone levels in women using hormonal contraceptives is not a reliable strategy for diag nosing menopause [10] . Importantly, VTE risk for users of estrogencontaining OCs increases with age. Therefore, for women who acquire car diovascular risk factors as they age, switching to a progestinonly or nonhormonal method is recommended [101] .
When is surgical sterilization appropriate?
For women who desire permanent cessation of fertility, laparoscopic or hysteroscopic tubal sterilization or vasectomy for a male partner are options. For women who have relative con traindications to laparoscopy or general anes thesia, such as obesity, medical comorbidities or adhesions from previous surgery, hystero scopic placement of tubal inserts is less invasive and can be performed under sedation. Older women are less likely to experience regret after permanent sterilization [19] .
How should clinicians counsel women aged 40 years or older about contraceptive use?
Counseling on initiation or continuation of contraception for women aged 40 years and older should be individualized and include benefits of available methods, agerelated risks of particular methods, agerelated fertil ity rates and risks of pregnancy complications due to age or co morbidities. As with younger women, highlighting the safest, most effective options, LARC, is recommended. There are no contraceptives that are contraindicated based on age alone [101] . Evidencebased resources are available to assist providers in discussing benefits and risks with patients. The 2010 US Medical Eligibility for Contraceptive Use provides current evidencebased guidelines on the safety of contraceptive methods for women with various medical conditions and charac teristics [101] . It is available for smart phones, online and in print.
What next?
Clinical trials that include older contraceptive users would provide additional data on the effec tiveness and safety of contraceptive use in this population, enabling women over 40 years of age and their clinicians, to make more informed choices.
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